Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03673124 · OUTCOME

Progression-free Survival (PFS)

Ribociclib and Letrozole Treatment in Ovarian Cancer · Source last updated 2025-12-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
90% Confidence Interval
Time frame
From date of protocol entry to date of first documented progression or death assessed up to approximately 55 months

What was measured

PFS was defined as the time from study entry to the first documented disease progression, or death from any cause, whichever occurs first. Disease progression was assessed by RECIST 1.1.

Analysis population: Eligible participants who received any amount of protocol therapy

Groups in this outcome

Ribociclib and Letrozole

Ribociclib 600 mg administered orally daily for 21 days followed by 7 days off in 28-day treatment cycle plus Letrozole 2.5 mg administered orally daily for 28 days.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ribociclib and Letrozole49

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
Ribociclib and Letrozole14.5Not reported10.128.8Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        10.1
        upper Limit
        28.8
        value
        14.5
denoms
  1. counts
    1. group Id
      OG000
      value
      49
    units
    Participants
description
PFS was defined as the time from study entry to the first documented disease progression, or death from any cause, whichever occurs first. Disease progression was assessed by RECIST 1.1.
dispersion Type
90% Confidence Interval
groups
  1. description
    Ribociclib 600 mg administered orally daily for 21 days followed by 7 days off in 28-day treatment cycle plus Letrozole 2.5 mg administered orally daily for 28 days.
    id
    OG000
    title
    Ribociclib and Letrozole
param Type
MEDIAN
population Description
Eligible participants who received any amount of protocol therapy
reporting Status
POSTED
time Frame
From date of protocol entry to date of first documented progression or death assessed up to approximately 55 months
title
Progression-free Survival (PFS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice